Gene–Gene Interactions Among PRKCA, NOS3 and BDKRB2 Polymorphisms Affect the Antihypertensive Effects of Enalapril

• Published in: Basic & clinical pharmacology & toxicology Vol. 120; no. 3; pp. 284 - 291
• Main Authors: Oliveira‐Paula, Gustavo H., Luizon, Marcelo R., Lacchini, Riccardo, Fontana, Vanessa, Silva, Pamela S., Biagi, Celso, Tanus‐Santos, Jose E.
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.03.2017
• Subjects: Adult; Angiotensin; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Antihypertensives; Blood pressure; Blood Pressure - drug effects; Bradykinin; Enalapril - pharmacology; Enalapril - therapeutic use; Enzyme inhibitors; Epistasis, Genetic; Female; Gene polymorphism; Genotype; Genotypes; Haplotypes; Humans; Hypertension - drug therapy; Kinases; Male; Middle Aged; Nitric oxide; Nitric Oxide Synthase Type III - genetics; Nitric Oxide Synthase Type III - metabolism; Nitric-oxide synthase; NOS3 protein; Pharmacogenomic Variants; Polymorphism; Polymorphism, Single Nucleotide; Protein kinase C; Protein Kinase C-alpha - genetics; Protein Kinase C-alpha - metabolism; Proteins; Receptor, Bradykinin B2 - genetics; Receptor, Bradykinin B2 - metabolism; Signal Transduction

Protein kinase C (PKC) signalling is critically involved in the control of blood pressure. Angiotensin‐converting enzyme inhibitors (ACEi) affect PKC expression and activity, which are partially associated with the responses to ACEi. We examined whether PRKCA (protein kinase C, alpha) polymorphisms...